Impact of the Frequency and Type of Procedures Performed in Nuclear Medicine Units on the Expected Radiological Hazard.

Nuclear medicine procedures play an important role in medical diagnostics and therapy. They are related to the use of ionizing radiation, which affects the radiological exposure of all of the persons involved in their performance. The goal of the study was to estimate the doses associated with the performance of various nuclear medicine procedures in order to optimize workload management. The analysis was performed for 158 myocardial perfusion scintigraphy procedures, 24 bone scintigraphies, 9 thyroid scintigraphies (6 with use of 131I and 3 with 99mTc), 5 parathyroid glands and 5 renal scintigraphies. In this evaluation, two possible locations of thermoluminescent detectors, used for measurements, were taken into consideration: in the control room and directly next to the patient. It was shown how the radiological exposure varies depending on the performed procedure. For high activity procedures, ambient dose equivalent registered in the control room reached the level over 50% of allowed dose limit. For example, ambient dose equivalent obtained in control room when performing bone scintigraphy only was 1.13 ± 0.3 mSv. It is 68% of calculated dose limit in the examined time span. It has been shown that risk associated with nuclear medicine procedures is influenced not only by the type of procedure, but also by the frequency of their performance and compliance with the ALARA principle. Myocardial perfusion scintigraphy accounted for 79% of all evaluated procedures. The use of radiation shielding reduced the obtained doses from 14.7 ± 2.1 mSv in patient's vicinity to 1.47 ± 0.6 mSv behind the shielding. By comparing the results obtained for procedures and dose limits established by Polish Ministry of Health, it is possible to estimate what should be the optimal division of duties between staff, so that everyone receives similar doses.

Selenium supplementation on plasma glutathione peroxidase activity in patients with end-stage chronic renal failure.

Patients with chronic renal failure (CRF) usually have a lower than healthy level of selenium (Se) in whole blood and plasma. Plasma glutathione peroxidase (GSH-Px) is synthesized mostly in the kidney. In CRF patients, activity of this enzyme is significantly reduced and its reduction increases with the progress of the disease. The aim of the study was to evaluate the effect of Se supplementation to CRF patients at various stages of the disease on Se concentration in blood components and on plasma GSHPx activity. The study group comprised 53 CRF patients at various stages of the disease supplemented with Se (200 microg/d for 3 mo as Se-enriched yeast, containing about 70% L-selenomethionine [SeMet]). The control group consisted of 20 healthy subjects. The Se concentration in blood components was measured spectrofluorometrically with 2,3-diaminonaphthalene as a complexing reagent. GSH-Px activity in red cell hemolysates and plasma was assayed by the coupled method with tert-butyl hydroperoxide as a substrate. The Se concentration in whole blood and plasma of CRF patients is significantly lower as compared with healthy subjects, but similar at all stages of the disease. In the patients' plasma, total protein and albumin levels are also significantly lower than in healthy subjects. Plasma GSH-Px activity in patients is extremely low, and contrary to Se concentration, it decreases linearly with the increasing stage of the illness. Se-supplied patients show an increased Se concentration in all blood components and at all disease stages, whereas plasma GSH-Px activity is enhanced only at the incipient stage of the disease. Se supply has no effect on plasma GSHPx activity in uremic patients at the end stage of the disease. Total plasma protein and albumin levels did not change after Se supplementation. Our data seem to show that in patients with CRF lower total protein and albumin levels in plasma may be the chief cause of the low blood and plasma Se concentrations. GSH-Px activity decreases along with the kidney impairment. At the end stage of the disease, Se supplementation in the form of Se-enriched yeast has no effect on the increase in plasma GSH-Px activity.